Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Frailty worsens surgery outcomes in old patients

27 Feb 2020

Frailty is associated with poor 1-year outcomes in elderly patients undergoing emergency general surgery (EGS), a recent study reports.

Researchers conducted a retrospective analysis of 468,459 elderly adults who underwent partial colectomy, small bowel resection, peptic ulcer disease repair, adhesiolysis or laparotomy. A validated claims-based frailty index was used to identify those who were prefrail, mildly frail and moderately-to-severely frail.

A total of 175,336 participants (37.4 percent) were prefrail, while 12.4 percent (n=58,056) and 3.6 percent (n=16,803) were mildly and moderately-to-severely frail, respectively; the remaining 218,264 were nonfrail. Fourteen percent of patients with any frailty received palliative care during index hospitalization.

The 30-day mortality was 15.7 percent (n=73,666), which grew to 24.7 percent (n=115,687) by day 180 and further to 30.4 percent (n=102,365) at 1 year. Crude mortality was highest among those with the most severe frailty.

Multivariable analysis confirmed that the risk of 30-day mortality was significantly elevated in those with prefrailty, mild and moderate-to-severe frailty, relative to the nonfrail comparators. These effects were consistent at 180 days and at 1 year. Notably, those at the highest levels of frailty were more than twice as likely to die at 1 year than nonfrail participants (hazard ratio, 2.30, 95 percent confidence intervals, 2.24–2.35).

Similarly, 1-year postdischarge outcomes, such as emergency department visits, rehospitalizations, stay in the intensive care and total hospital encounters, were all significantly worse in patients with any frailty. Greater severities of frailty resulted in higher risks across all outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.